Should You Already Consider Disposing Your Humana (HUM) Shares?

Oakmark Funds, an investment management firm, published its “Oakmark Global Select Fund” second quarter 2022 investor letter – a copy that can be downloaded here. The Oakmark Global Select Fund returned -16.7% for the quarter ending June 30, underperforming the MSCI World Index (NET), which returned -16.2%. Year-to-date, the Fund returned -22.6% compared to the benchmark’s return of -20.5%. Since its September 2006 inception, the Fund has earned an annualized return of 6.9% per year. Go over the fund’s top 5 positions to have a glimpse of its finest picks for 2022.

In its Q2 2022 investor letter, Oakmark Global Select Fund mentioned Humana Inc. (NYSE:HUM) and explained its insights for the company. Founded in 1961, Humana Inc. (NYSE:HUM) is a Louisville, Kentucky-based health insurance company with a $61.1 billion market capitalization. Humana Inc. (NYSE:HUM) delivered a 4.27% return since the beginning of the year, while its 12-month returns are up by 4.36%. The stock closed at $483.69 per share on July 20, 2022.

Here is what Oakmark Global Select Fund has to say about Humana Inc. (NYSE:HUM) in its Q2 2022 investor letter:

“During the quarter, we also sold our position in Humana (NYSE:HUM) in favor of names that, in our opinion, offer more potential upside. Geographically, we ended the quarter with 53% of the portfolio in the U.S., 38% in the U.K. and Europe, and 9% in Asia.”

Copyright: andreypopov / 123RF Stock Photo

Our calculations show that Humana Inc. (NYSE:HUM) fell short and didn’t make it on our list of the 30 Most Popular Stocks Among Hedge Funds. Humana Inc. (NYSE:HUM) was in 66 hedge fund portfolios at the end of the second quarter of 2022, compared to 66 funds in the previous quarter. Humana Inc. (NYSE:HUM) delivered a 3.91% return in the past 3 months.

In April 2021, we also shared another hedge fund’s views on Humana Inc. (NYSE:HUM) in another article. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters 2022 Q2 page.

Disclosure: None. This article is originally published at Insider Monkey.